At a glance
ClinicalIndex Comparison RecordPhase 1Active· 36 target
Drug / intervention
RP2 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors
In Brief
A Phase 1 clinical trial evaluating RP2 and nivolumab for Cancer. Active but no longer recruiting, targeting 36 participants across 6 sites in 2 countries.
Detailed Summary
RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesSpain, United Kingdom
Collaborators--
Timeline
Phase 1Active
20202021202220232024202520262027
Enrollment StartOct 2019
First PostedApr 2020
TodayJul 2026
Primary CompletionOct 2026
First PostedApr 7, 2020
Enrollment StartOct 17, 2019
Primary CompletionOct 31, 2026
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 6.2 years agoPrimary completion in 4 months
Interventions
RP2biological
Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
nivolumabbiological
Programmed death receptor (PD-1) blocking antibody